InflaRx to present late-breaking preclinical izicopan data at ASN Kidney Week 2026
IFRX•InflaRx said it will present late-breaking preclinical data on oral C5aR1 antagonist izicopan at Kidney Week 2026 on Oct. 22, 2026. The findings indicate therapeutic potential in kidney disease models, and the company plans development in ANCA-associated vasculitis.
1. Presentation planned
InflaRx announced it will present late-breaking preclinical data on oral C5aR1 antagonist izicopan at Kidney Week 2026. The poster is scheduled for Oct. 22, 2026, ahead of planned development in ANCA-associated vasculitis. The preclinical findings indicate therapeutic potential in kidney disease models, while prior clinical work cited showed a clean safety profile.
